Pomalidomide in Combination with Low-Dose Dexamethasone as the Treatment of “Double Refractory” Multiple Myeloma

Background. The development of radical therapy for multiple myeloma (MM) is still a pressing problem. This progressive disease requires repeated courses of therapy using drugs without cross-resistance. The prognosis of “double refractory” MM which is resistant to key antitumor drugs, first generatio...

Full description

Bibliographic Details

Published in:	Клиническая онкогематология
Main Authors:	AV Petrov, DV Motorin, OS Pokrovskaya, ES Urnova, MV Nareiko, DV Babenetskaya, YuA Alekseeva, LL Girshova, LP Mendeleeva, AYu Zaritskii
Format:	Article
Language:	Russian
Published:	Practical Medicine Publishing House 2017-07-01
Subjects:	multiple myeloma “double-refractoriness” immunomodulating agents pomalidomide
Online Access:	http://bloodjournal.ru/wp-content/uploads/2017/09/10.pdf